SAVA News and Press, Cassava Sciences Inc. From 03/25/24

2024-03-25 11:58:56 ET More on Cassava Sciences Cassava Sciences: Where Did All The Mild Alzheimer's Disease Patients Go? Cassava Sciences And Alzheimer's Disease: Opaque Clarity Biotech And Pharma Diversification Pays Off Cassava Sciences again under scrutin...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - March 25, 2024) - Faruqi & Faruqi, LLP, a leading national ...

An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials Continue as Planned, Without Modification. Final Clinical Safety Data for S...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - March 24, 2024) - Faruqi & Faruqi, LLP, a leading national ...

2024-03-20 04:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-17 09:42:44 ET Summary Cassava Sciences presented different charts at the CTAD and Lisbon conferences, causing speculation about the reasons for the discrepancy. Cassava Sciences combined some mild Alzheimer's disease patients with mild cognitive impairment patients and ot...

2024-03-12 10:37:00 ET Cassava Sciences Inc (NASDAQ: SAVA) is in focus today after it again came under scrutiny over research involving its Alzheimer’s drug. FDA report questions Alzheimer’s drug trial results of $SAVA An FDA (Food & Drug Administration) report...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - March 11, 2024) - Faruqi & Faruqi, LLP, a leading national ...

2024-03-11 19:15:08 ET A lab run a City University of New York (CUNY) scientist with ties to Cassava Sciences ( NASDAQ: SAVA ) and its Alzheimer's candidate simufilam was flagged with a multitude of issues during a September 2022 US FDA inspection.... Read the full article on ...

AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced plans to present a virtual oral presentation at the International Conference on Alzheimer’s and Parkison&...